Cheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, Yung-Yeh Su, Sz-Chi Chiu, Li-Yuan Bai, Yan-Shen Shan, Li-Tzong Chen, Shih-Chang Chuang, De-Chuan Chan, Chia-Jui Yen, Cheng-Ming Peng, Tai-Jan Chiu, Yen-Yang Chen, Jen-Shi Chen, Nai-Jung Chiang, Wen-Chi Chou
BACKGROUND/OBJECTIVES: Liposomal irinotecan plus 5-fluorouracil and leucovorin (nal-IRI + 5-FU/LV) provides survival benefits for metastatic pancreatic adenocarcinoma (mPDAC) refractory to gemcitabine-based treatment, mainly gemcitabine plus nab-paclitaxel (GA), in current practice. Gemcitabine plus S-1 (GS) is another commonly administered first-line regimen before nab-paclitaxel reimbursement; however, the efficacy and safety of nal-IRI + 5-FU/LV for mPDAC after failed GS treatment has not been reported and was therefore explored in this study...
March 25, 2024: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]